Pr. Cleo Bishop, PhD
SAB Member
With a PhD in Biological Sciences from University College London, Prof. Bishop has dedicated her career to studying senescence and cancer. She serves as the Director of the Blizard Institute and heads the Phenotypic Screening Facility at Queen Mary University of London (QMUL). A pioneer in identifying regulators of senescence, including the biomarker p16, Prof. Bishop is a distinguished academic and researcher. She has held numerous academic positions and currently leads the senescence research program at the Blizard Institute, contributing to major advancements in the field.
Dr. David Bernard, PhD
SAB member
A CNRS Research Director, Dr. Bernard leads a team at the Cancer Research Center of Lyon (CRCL) focused on mechanisms of senescence escape and the links between ion flux, mitochondria, and cancer development. After completing postdoctoral research at University College London and the University of Brussels, he joined the CRCL in 2011. His influential work sheds light on aging biology and oncogenic processes, positioning StarkAge at the forefront of senescence research.
Dr. Fabrizio d’Adda di Fagagna, PhD
SAB member
Holding a PhD in Molecular Genetics from SISSA, Trieste, Dr. d’Adda di Fagagna is renowned for his discoveries in replicative senescence and telomere biology. Currently a researcher at the Consiglio Nazionale delle Ricerche (CNR) in Pavia, Italy, he established his own laboratory at IFOM in Milan in 2003. He has received numerous accolades, including two ERC Advanced Grants and the EACR Young Investigator Award. His groundbreaking research on DNA damage response and cellular aging has earned him international recognition, offering StarkAge unique expertise in telomere biology and senescence.
Pr. Michail Ignatiadis MD, PhD
SAB member
An MD, PhD, and Director of the Breast Oncology Clinic at the Jules Bordet Institute, Belgium, Prof. Ignatiadis is a leading figure in breast oncology and Chair of the EORTC Breast Cancer Research Group. An active member of research and clinical trial oversight committees, he has led numerous academic and industry-sponsored trials. His expertise in developing innovative therapies and managing complex oncology projects strengthens StarkAge’s scientific strategy.
